-$0.08 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter

Share on StockTwits

Wall Street brokerages expect that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will post ($0.08) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.11). Catalyst Pharmaceuticals posted earnings of ($0.05) per share during the same quarter last year, which indicates a negative year over year growth rate of 60%. The business is scheduled to report its next quarterly earnings report on Wednesday, November 14th.

According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full-year earnings of ($0.31) per share for the current fiscal year, with EPS estimates ranging from ($0.38) to ($0.24). For the next financial year, analysts expect that the firm will post earnings of ($0.16) per share, with EPS estimates ranging from ($0.35) to ($0.07). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Catalyst Pharmaceuticals.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02.

A number of equities analysts have issued reports on CPRX shares. BidaskClub lowered Catalyst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 8th. HC Wainwright set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 22nd. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research report on Monday, August 13th. ValuEngine raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 14th. Finally, Oppenheimer started coverage on Catalyst Pharmaceuticals in a research report on Thursday, July 12th. They issued a “buy” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $5.21.

Catalyst Pharmaceuticals stock opened at $3.24 on Friday. Catalyst Pharmaceuticals has a one year low of $2.18 and a one year high of $4.51. The company has a market cap of $348.84 million, a P/E ratio of -15.43 and a beta of 1.70.

Several hedge funds have recently bought and sold shares of CPRX. Lido Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at approximately $142,000. MetLife Investment Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $157,000. New York State Common Retirement Fund raised its position in shares of Catalyst Pharmaceuticals by 47.6% during the 1st quarter. New York State Common Retirement Fund now owns 74,994 shares of the biopharmaceutical company’s stock valued at $179,000 after acquiring an additional 24,200 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Catalyst Pharmaceuticals during the 1st quarter valued at approximately $230,000. Finally, Rhumbline Advisers raised its position in shares of Catalyst Pharmaceuticals by 34.7% during the 2nd quarter. Rhumbline Advisers now owns 90,725 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 23,383 shares in the last quarter. 51.49% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Further Reading: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply